331 related articles for article (PubMed ID: 30736852)
1. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
[TBL] [Abstract][Full Text] [Related]
2. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
Høgdall D; Lewinska M; Andersen JB
Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.
Panya A; Thepmalee C; Sawasdee N; Sujjitjoon J; Phanthaphol N; Junking M; Wongkham S; Yenchitsomanus PT
Cancer Immunol Immunother; 2018 Oct; 67(10):1579-1588. PubMed ID: 30056600
[TBL] [Abstract][Full Text] [Related]
4. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Gbolahan O; Hashemi-Sadraei N; O'Neil B
J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
[TBL] [Abstract][Full Text] [Related]
5. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
[TBL] [Abstract][Full Text] [Related]
6. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
Feng KC; Guo YL; Liu Y; Dai HR; Wang Y; Lv HY; Huang JH; Yang QM; Han WD
J Hematol Oncol; 2017 Jan; 10(1):4. PubMed ID: 28057014
[TBL] [Abstract][Full Text] [Related]
7. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
Sangsuwannukul T; Supimon K; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107069. PubMed ID: 33242709
[TBL] [Abstract][Full Text] [Related]
9. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
10. [The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab].
Kan N; Yoshikawa K; Matsushita N; Fujii T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1759-61. PubMed ID: 24393913
[TBL] [Abstract][Full Text] [Related]
11. Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study.
Wong M; Kim J; George B; Eriksen C; Pearson T; Robbins J; Zimmerman MA; Hong JC
J Surg Res; 2019 Oct; 242():23-30. PubMed ID: 31059945
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case.
Higuchi R; Yamamoto M; Hatori T; Shimizu K; Imai K; Takasaki K
Surg Today; 2006; 36(6):559-62. PubMed ID: 16715430
[TBL] [Abstract][Full Text] [Related]
14. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma.
Kida A; Mizukoshi E; Kitahara M; Miyashita T; Goto S; Kamigaki T; Takimoto R; Asai J; Kakinoki K; Urabe T; Tomita K; Kaneko S
Int J Cancer; 2024 Feb; 154(4):738-747. PubMed ID: 37676069
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of the Lymph Node Ratio in Surgical Patients With Distal Cholangiocarcinoma.
Li X; Lin H; Sun Y; Gong J; Feng H; Tu J
J Surg Res; 2019 Apr; 236():2-11. PubMed ID: 30694756
[TBL] [Abstract][Full Text] [Related]
16. Evaluating a preoperative protocol that includes magnetic resonance imaging for lymph node metastasis in the Cholangiocarcinoma Screening and Care Program (CASCAP) in Thailand.
Songthamwat M; Chamadol N; Khuntikeo N; Thinkhamrop J; Koonmee S; Chaichaya N; Bethony J; Thinkhamrop B
World J Surg Oncol; 2017 Sep; 15(1):176. PubMed ID: 28931405
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
18. Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
Zanetti M
J Immunol; 2015 Mar; 194(5):2049-56. PubMed ID: 25710958
[TBL] [Abstract][Full Text] [Related]
19. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns.
Jiraviriyakul A; Songjang W; Kaewthet P; Tanawatkitichai P; Bayan P; Pongcharoen S
World J Gastroenterol; 2019 Aug; 25(29):3941-3955. PubMed ID: 31413529
[TBL] [Abstract][Full Text] [Related]
20. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment.
Cholangiocarcinoma Working Group
Dig Liver Dis; 2020 Dec; 52(12):1430-1442. PubMed ID: 32952071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
